SLC2A2 Genotype

Your body's ability to sense and move sugar depends on a small number of specialized proteins, and one of the most important of them is built from a gene called SLC2A2. If you carry certain variants in this gene, your liver, kidneys, pancreas, and gut handle sugar differently than most people, which can change how diabetes develops in your family and how well certain diabetes medications work for you.

This test reads your two copies of SLC2A2 once. The result does not change over your lifetime. What changes is how you use the information, because the same genotype carries different implications depending on whether you are managing blood sugar, choosing a diabetes drug, or planning a family.

What SLC2A2 Actually Does

SLC2A2 (solute carrier family 2 member 2) is the gene for a transporter protein called GLUT2 (glucose transporter type 2). GLUT2 sits in the membranes of cells in your liver, kidney tubules, intestinal lining, and pancreatic islets, where it moves sugar in and out depending on which way the concentration is higher. It is also expressed in parts of the brain involved in feeding behavior. GLUT2 is one of the main ways your body senses changes in blood sugar and adjusts insulin release and sugar storage in response, although its role in human beta-cell insulin secretion appears less dominant than what has been observed in mice.

When both copies of SLC2A2 are severely broken, this sensing system fails in obvious ways. When only one common variant is present, the effects are subtler and tend to show up in how your body responds to a specific class of diabetes medication.

Fanconi-Bickel Syndrome

When a person inherits two damaged copies of SLC2A2 (one from each parent), they develop Fanconi-Bickel syndrome (FBS), a rare condition in which the liver, kidneys, and blood sugar regulation all go wrong together. The hallmarks are an enlarged liver from stored sugar, kidney tubules that leak nutrients into urine, and unstable blood sugar that can swing between too high after meals and too low between them.

A case study of one person with a Fanconi-Bickel-causing mutation showed kidney tissue with almost no GLUT2 protein and major problems in the tubules that filter blood, which explained severe acid buildup and bicarbonate loss in the urine. Other case work shows that different mutations cause damage in different ways: a truncating mutation in the gene's coding sequence led to overexpression of a dysfunctional GLUT2 protein, while a mutation in a non-coding region left the protein intact but altered small regulatory molecules called microRNAs (which fine-tune which proteins cells make by influencing how messenger RNA is read), particularly miR-29a-3p, which is involved in insulin production.

Neonatal Diabetes

In a study of 104 infants who developed diabetes in the first months of life and whose more common genetic causes had already been ruled out, 5% had two damaged copies of SLC2A2. Among the subset whose diabetes was transient (it appeared, then resolved), SLC2A2 explained 16% of cases. The pattern of low insulin output at very high blood sugar levels suggests that GLUT2 helps the pancreas decide when to release insulin in humans, not just in lab animals.

This matters even for adults getting tested, because neonatal diabetes from SLC2A2 mutations often shows up before the classic Fanconi-Bickel features appear (four of five patients in the study presented with isolated diabetes first). Knowing the gene status changes how a family interprets a baby's early diabetes and what they watch for as the child grows.

Type 2 Diabetes Risk and Progression

Beyond the rare two-copy disorders, common variants in SLC2A2 nudge ordinary type 2 diabetes risk. In the Finnish Diabetes Prevention Study, people with impaired glucose tolerance who carried certain SLC2A2 variants had about three times the risk of progressing to full type 2 diabetes compared to non-carriers. Lifestyle intervention reduced this gene-related risk, suggesting that the inherited tendency is not destiny.

A separate study of 210 people found a silent variant called rs5404 in SLC2A2 (one that does not change the protein sequence but may alter how the gene is read) showed complex links with type 2 diabetes and elevated HbA1c (a three-month measure of average blood sugar), particularly when combined with variants in another gene called CAPN10.

Metformin Response

One of the most practical reasons to know your SLC2A2 status is how it predicts your response to metformin, the most widely prescribed type 2 diabetes drug. A large genome-wide study of 13,123 people found that those who carried two copies of the C variant at a position called rs8192675 had up to 0.33% greater HbA1c reduction on metformin than people with two T copies. That extra benefit is roughly equivalent to taking about 550 mg more metformin, and the effect was strongest in people with obesity.

A separate study of 508 people newly diagnosed with type 2 diabetes confirmed the pattern: C carriers on metformin alone had a larger drop in fasting glucose than TT carriers. The biological mechanism appears to involve liver tissue, where the C variant is linked to lower SLC2A2 expression. One important caveat: this same association did not replicate in a prediabetes population in the Diabetes Prevention Program, so the variant's effect on metformin response may be specific to people with established type 2 diabetes rather than those treated for prediabetes. If you are starting metformin for diagnosed type 2 diabetes, knowing your genotype gives you a way to set realistic expectations and, if your response is poor despite a favorable genotype, a reason to investigate other causes.

What This Means For Your Family

Because Fanconi-Bickel syndrome and SLC2A2-related neonatal diabetes are recessive (they require two damaged copies to cause disease), having one damaged copy makes you a carrier but does not cause obvious disease. If you and a partner are both carriers of a damaging variant, each child has a one in four chance of inheriting both copies. This is most relevant if there is consanguinity in your family or a history of unexplained neonatal diabetes, liver enlargement, or kidney tubule problems. In one large Palestinian cohort, 85% of Fanconi-Bickel cases came from consanguineous parents.

One-Time Test, Lifetime Use

Your SLC2A2 genotype is fixed at conception and does not change. You will never need to retest the gene itself unless the original variant call was made by a method (like a SNP chip) where a confirmatory sequencing run might be warranted. What you do need to retest is the downstream biology this genotype influences. That means tracking HbA1c, fasting glucose, fasting insulin, and ideally an oral glucose tolerance test, especially if you have any other diabetes risk factors. General diabetes screening guidance suggests annual metabolic labs as a reasonable cadence, dropping to every 3 to 6 months if you are making changes or watching a borderline result.

When a Genetic Result Can Mislead You

Genetic tests look like simple yes-or-no answers, but several technical issues can distort what you see on the report. The four most important to understand:

• Panel coverage: the assay reports only the specific variants it is designed to detect. A negative result does not rule out rare or novel variants elsewhere in SLC2A2 that the panel does not look for.
• Ancestry and allele frequency: some SLC2A2 variants are common in certain populations and rare in others, which changes the practical meaning of a positive result. Risk estimates from one population do not always transfer.
• Variants of uncertain significance: sequencing sometimes turns up an unexpected variant whose clinical meaning is not yet known. These reports require careful interpretation rather than action.
• Clinical-grade versus consumer testing: direct-to-consumer reports for SLC2A2 are not always confirmed by a clinical-grade method. If a finding would change your care, a confirmatory test is worth running.

What to Do With an Out-of-Pattern Result

If your test reveals two damaging SLC2A2 variants, the next steps depend on age and symptoms. In adults this is rare, but if found, work with an endocrinologist or genetic counselor to investigate liver size, kidney tubule function (urine glucose, amino acids, phosphate), and a full metabolic profile. If your test shows you carry one damaging variant, the most useful step is a conversation with biological siblings, parents, and any future co-parent, plus genetic counseling if you are planning children. If your test shows a common metformin-response variant like rs8192675, share this with whoever manages your blood sugar so they can interpret your response to that medication in context.

A genetic counselor is worth involving when the result is unexpected, when a variant of uncertain significance appears, or when family planning is on the table. For common type 2 diabetes risk variants alone, a counselor is usually unnecessary, but tightening your lipid panel, fasting insulin, HbA1c, and oral glucose tolerance testing schedule is.